- The American Cancer Society has updated its 2012 cervical cancer screening guidelines.
- The guidelines reference patients who are initiating cervical cancer screening, have previously had all normal cervical cancer screening results, or have been returned to routine cervical cancer screening based on follow-up recommendations from the Risk-Based Management Consensus Guidelines.
- The recommendations apply to all asymptomatic individuals with a cervix, regardless of their sexual history or HPV vaccination status.
- Individuals should initiate cervical cancer screening at age 25 years and undergo primary HPV testing every 5 years through age 65 years.
- If primary HPV testing is not available, cotesting (HPV testing in combination with cytology) every 5 years or cytology alone every 3 years is recommended.
- Individuals aged ≥65 years who have no history of cervical intraepithelial neoplasia 2+ within the last 25 years and who have documented adequate negative prior screening in the prior 10 years can discontinue cervical cancer screening.
- Screening may be discontinued in individuals of any age with limited life expectancy.
- These recommendations do not apply to individuals at increased risk for cervical cancer because of solid organ or stem cell transplantation, HIV infection or immunosuppression from other causes, or in utero exposure to diethylstilbestrol.